NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Formation Bio, the AI-native pharmaceutical company revolutionizing drug development, today announced the appointment of four world-class leaders to its senior ...

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs ...

Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses ...

Add Yahoo as a preferred source to see more of our stories on Google. Canadian PM Trudeau tours a Sanofi facility in Toronto (Reuters) - AI-based drug developer Formation Bio said on Wednesday that it ...

Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to ...

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals. This next-generation central ...

Formation Bio Inc., a startup using artificial intelligence to speed up drug development, today announced that it has closed a mammoth $372 million investment. Andreessen Horowitz led the Series D ...

Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials. Now he’s raised some $615 million from top investors ...

Formation Bio CEO Benjamine Liu joins 'Fast Money' as Formation comes in at #37 on the Disruptor 50 list. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get ...

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Formation Bio and Jiangsu Chia Tai Feng Hai Pharmaceutical Co., LTD. (CTFH) today announced Formation Bio's acquisition of worldwide rights, excluding Greater ...

(Reuters) - AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi. The ...

Former Pfizer, BenevolentAI, Incyte, and AMAG executives join to strengthen clinical, technology, financial, and scientific leadership as company scales its AI-native pharma model NEW YORK, Sept. 18, ...